Signal · Supplier & Corporate Risk
Equipment House unit secures exclusive ETHAMOLIN distribution rights
What the source reported
Source-reported<p><img src="https://argaamplus.s3.amazonaws.com/660d0681-157a-4539-b8d4-f0227f31876f.png"></p> <p class="ckeCaption" ><!--StartFragment-->Equipment House's subsidiary secured exclusive rights to distribute ETHAMOLIN® in Saudi Arabi</p> <hr> <div data-olk-copy-source="MessageBody" >Scientific and Medical Equipment House Co. (<a href="https://www.argaam.com/en/tadawul/tasi/equipment-house" target="_blank">Equipment House</a>) said its wholly owned subsidiary, Qurqas Pharmaceutical Warehouse Co., secured exclusive rights to distribute ETHAMOLIN in Saudi Arabi.</div> <div> <p ></p> <p >The move comes under an agreement with US-based QOL Medical LLC, according to a <strong>Tadawul </strong>statement.</p> <p ></p> <p >The agreement has been registered with the Ministry of Commerce and will remain valid until 2030.</p> <p ></p> <p >ETHAMOLIN, approved by the US Food and Drug Administration (FDA), is used for the sclerotherapy of bleeding esophageal varices, in accordance with its approved indications, Equipment House said.</p> <p ></p> <p >Qurqas Pharmaceutical Warehouse currently supplies the drug to the National Unified Procurement Co. (NUPCO), with the related revenue reflected in the company's financial statements, it added.</p> <p ></p> <p >Equipment House expects the exclusive distribution rights to support sustainable revenue and growth throughout the agreement period. Registration of the drug with the Saudi Food and Drug Authority (SFDA) could also create opportunities to expand its availability across the Kingdom's healthcare sector, the company said.</p> <p ></p> <p >The company said it is currently completing the procedures to register the distribution rights and the drug with the SFDA, paving the way for its subsidiary to obtain the final drug license in its name.</p> <p ></p> <p >The agreement is part of Equipment House’s strategy to expand its operations in specialized and niche pharmaceuticals.</p> <p ></p> <p >Equipment House noted that it will announce any material developments in due course.</p> </div>
- Publication
- Argaam - Company Disclosures · Stock Exchange/Regulatory Announcements
- Published
- 22nd October 2026
- Original report
- argaam.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supplier & Corporate Risk
- Geography
- Saudi Arabia, UAE
- Organisations
- None identified
- Collected
- 22nd October 2026 · 14:58
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Moderate (27.0/100). Strongest contributor: Procurement Impact (18.0/30 points). Limiting factor: Impact-Scale Specificity (0.0/10 points). Initial Confidence Low (26.75/100, data sufficiency: Partial). Strongest contributor: Source Authority (12.0/40 points). Limiting factor: Corroboration (2.5/25 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Impact-Scale Specificity